Comparing Nivolumab vs Pembrolizumab

View side-by-side comparisons of medication uses, ratings, cost, side effects and interactions.
Nivolumab	Pembrolizumab	Enter another drug to compare

View side-by-side comparisons of medication uses, ratings, cost, side effects and interactions.
Nivolumab	Pembrolizumab	Enter another drug to compare
Prescription only Prescribed for Head and Neck Cancer, Esophageal Carcinoma, Hepatocellular Carcinoma, Colorectal Cancer, Gastric Cancer, Hodgkin's Lymphoma, Malignant Pleural Mesothelioma, Melanoma, Melanoma -... View more	Prescription only Prescribed for Bladder Cancer, Breast Cancer, Biliary Tract Tumor, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Carcinoma, Gastric Cancer, Head and Neck Cancer, Hepatocellular... View more	Related suggestions Non Small Cell Lung Cancer Tagrisso Keytruda Opdivo Alimta Avastin Alecensa Renal Cell Carcinoma Sutent Votrient Inlyta Keytruda Opdivo Cabometyx Colorectal Cancer Oxaliplatin Xeloda Capecitabine Fluorouracil Avastin Leucovorin Melanoma, Metastatic Yervoy Mekinist Keytruda Tafinlar Ipilimumab Opdivo
More about Nivolumab	More about Pembrolizumab
Ratings & Reviews
Nivolumab has an average rating of 5.9 out of 10 from a total of 139 ratings on Drugs.com. 53% of reviewers reported a positive effect, while 40% reported a negative effect.	Pembrolizumab has an average rating of 5.2 out of 10 from a total of 282 ratings on Drugs.com. 43% of reviewers reported a positive effect, while 44% reported a negative effect.
View all 139 reviews	View all 282 reviews
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified.
Fatigue (11.5%) Rash (8.6%) Diarrhea (7.2%) Weakness (7.2%) Itching (5.8%) Tiredness (5.0%) Loss of appetite (4.3%) View all Nivolumab side effects	Fatigue (12.1%) Weakness (7.4%) Tiredness (6.7%) Shortness of breath (6.4%) Loss of appetite (6.0%) Itching (4.6%) Diarrhea (4.3%) View all Pembrolizumab side effects
Drug Class
Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)	Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
Generic Availability
N/A	N/A
Pricing and Coupons * Prices are without insurance
We could not find an exact match for this medicine. Try searching the Price Guide directly.	We could not find an exact match for this medicine. Try searching the Price Guide directly.
Get free Discount Card	Get free Discount Card

Dosage Forms
N/A	N/A
Brand Names
Opdivo	Keytruda
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value.
640.8 hours	624 hours
CSA Schedule ¹ View glossary of CSA terms
N Not a controlled drug Is not subject to the Controlled Substances Act.	N Not a controlled drug Is not subject to the Controlled Substances Act.
Pregnancy Category
Summary unavailable. See the full pregnancy warnings document.	D Category D Positive evidence of risk See the full pregnancy warnings document.
Drug Interactions
A total of 591 drugs are known to interact with Nivolumab: 3 major drug interactions (6 brand and generic names) 588 moderate drug interactions (2069 brand and generic names)	A total of 591 drugs are known to interact with Pembrolizumab: 3 major drug interactions (6 brand and generic names) 588 moderate drug interactions (2069 brand and generic names)
Alcohol/Food/Lifestyle Interactions
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider.	No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider.
Disease Interactions
Hepatic impairment Pneumonitis HSCT Myasthenia gravis Organ transplant	Immune system disorder HSCT Myasthenia gravis Organ transplant Colitis Hepatic impairment Multiple myeloma Pneumonitis Thyroid disease
First Approval Date
December 22, 2014	N/A
WADA Class View classifications
N/A	N/A
More Information
Side effects Drug interactions Dosage Pregnancy warnings Breastfeeding warnings Support group En español	Side effects Drug interactions Dosage Pregnancy warnings Breastfeeding warnings Support group En español
Patient Resources
Nivolumab uses	Pembrolizumab uses
Professional Resources
Monograph (AHFS) Prescribing information	Monograph (AHFS) Prescribing information
Related Treatment Guide
Head and Neck Cancer Esophageal Carcinoma Hepatocellular Carcinoma Colorectal Cancer Gastric Cancer Hodgkin's Lymphoma Malignant Pleural Mesothelioma Melanoma Melanoma - Metastatic Non Small Cell Lung Cancer Renal Cell Carcinoma Stomach Cancer Urothelial Carcinoma show all	Bladder Cancer Breast Cancer Biliary Tract Tumor Cervical Cancer Colorectal Cancer Endometrial Cancer Esophageal Carcinoma Gastric Cancer Head and Neck Cancer Hepatocellular Carcinoma Hodgkin's Lymphoma Malignant Pleural Mesothelioma Melanoma Melanoma - Metastatic Merkel Cell Carcinoma Non Small Cell Lung Cancer Ovarian Cancer Primary Mediastinal Large B-cell Lymphoma Renal Cell Carcinoma Solid Tumors Squamous Cell Carcinoma Urothelial Carcinoma show all

¹ The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Comparing Nivolumab vs Pembrolizumab

See also:

Yervoy

Alecensa

Lumakras

Enhertu

Opdivo Qvantig

Rybrevant

Keytruda

Avastin

Tagrisso

Herceptin

Further information

Comparing Nivolumab vs Pembrolizumab

See also:

Further information

Compare Drugs